Replimune

dominoes fall series fail
Biotech

Krystal discontinues melanoma study after FDA's Replimune rebuff

The FDA’s rebuff of Replimune’s melanoma candidate has rippled across the industry, prompting Krystal Biotech to shutter a clinical trial.
Gabrielle Masson Aug 21, 2025 10:50am
Image of a neon sign with the word no lit up next to an unlit yes

Replimune's request for melanoma approval rejected by FDA

Jul 22, 2025 8:45am
Photo of a parachutes opened with a dark blue sky in the background

John Cox gets new biotech CEO gig at Dyne—Chutes & Ladders

Mar 29, 2024 9:30am
end of the road road block shut down closed blocked

Replimune shares halve as skin cancer drug fails phase 2

Dec 5, 2023 10:35am
Parachute

New year, new C-suite execs—Chutes & Ladders

Jan 6, 2023 9:30am
exit

Replimune axes CMO role and CMO Pirzkall along with it

Aug 26, 2021 7:20am